Most recurrent variants involve activating mutations of KRAS and NRAS, and glycine residues 12 and 13 (G12/13) are the most common mutation sites in RAS proteins in ALL (Li et al., 2020; Zhang et al., 2011). Here, KRAS is linked to acute lymphoblastic leukemia.